Gandhinagar News

Brain Cancer Market, Epidemiology, and Market Forecast Analysis Report

 Breaking News
  • No posts were found

Brain Cancer Market, Epidemiology, and Market Forecast Analysis Report

April 23
16:20 2021
Brain Cancer Market, Epidemiology, and Market Forecast Analysis Report

DelveInsight Business Research LLP
DelveInsight’s ‘Brain Cancer Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Brain Cancer, historical and forecasted epidemiology as well as the Brain Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

What is Brain Cancer?

A brain tumor, known as an intracranial tumor, central nervous system (CNS) tumors represent a group of diseases that have in common the abnormal development of mass lesions in the brain, spinal cord or its coverings.

How Brain Cancer affected population?

Brain Cancer Epidemiology in 2020-

  • In the United States, the incidence of Brain Tumors was 13,534 in males and 9,522 in females.
  • The total incident population of Primary Brain Tumors in the 7M was estimated to be 60,246.
  • Japan had 8,275 incident cases of Primary Brain Tumors.

To know more, request sample pages @Brain Cancer Market Landscape

Brain Cancer Market Outlook

 

The Brain Tumors market size in the 7MM was estimated to be USD 2,089.4 Million in 2020, which is expected to show a positive growth at a CAGR of 4.19% during the study period 2018–2030.

Brain tumors, specifically HGGs are very difficult tumors to treat due to the problems in completely removing the tumor and their resistance to radiotherapy and chemotherapy. As there is no ideal treatment, therefore it is quite challenging as some cells may respond well to certain therapies, while others may not be affected at all. Because of this, the treatment plan for the indication may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by the additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery. Treatment is palliative and may include surgery, radiation therapy and/or chemotherapy. The best treatment options for each person depends on many factors like the size and location of the tumor, the extent to which the tumor has grown into the surrounding normal brain tissues, and the affected person’s age and overall health.

What are the Brain Cancer market drivers?

Robust pipeline activity, upcoming launches and approval, increasing awareness programs, increase in reimbursement and insurance policies, improved treatment deliverance are the Brain Cancer market drivers.

What are the Brain Cancer market barriers?

Use of off-label therapies and generics, high-treatment costs, high recurrence rate, multiple treatment challenges are the brain cancer market barriers.

Which are the leading companies in Brain Cancer market?

The Brain Cancer market dynamics is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world and the expected launch of emerging therapies during the forecast period. Key players such as Bayer, Diffusion Pharmaceuticals, VBL Therapeutics, AstraZeneca, DNAtrix, Kintara Therapeutics, Oncoceutics, KaryoPharma, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Immunomic Therapeutics, Inovio Pharmaceuticals, Orbus Therapeutics, Novartis, Ziopharm and others are involved in developing treatments for Brain Cancer.

The potential candidates with promising results in the late- or phase III stage of clinical development include Ofranergene obadenovec (VB-111; VBL Therapeutics), Trans Sodium Crocetinate (Diffusion Pharmaceuticals), Eflornithine (Orbus Therapeutics) and Regorafenib (Bayer). Out of these, Orbus therapeutics’ Eflornithine is the only therapy being investigated solely for recurrent anaplastic astrocytoma (AA) while a majority of therapies in the pipeline are being investigated for GBM.

Followed by the late-stage products, a wide array of mid-stage or phase II promising interventions are expected to be launched in the near future in the market which includes Durvalumab (MEDI4736; MedImmune), Tasadenoturev (DNX-2401; DNAtrix), ONC201 (Oncoceutics), Selinexor (KPT-330; Karyopharm Therapeutics), VBI-1901 (VBI Vaccines), Paxalisib (GDC-0084; Kazia Therapeutics), AV-GBM-1 (Aivita Biomedical), MDNA55 (Medicenna Therapeutics), VAL-083 (Dianhydrogalactitol; DelMar Pharmaceuticals), ITI-1000 (pp65 DC Vaccine; Immunomic Therapeutics), Everolimus (Novartis), Ad-RTS-hIL-12 in combination with Veledimex (Ziopharm) and INO-5401 + INO-9012 + Cemiplimab (REGN2810; Inovio Pharmaceuticals).

 

Table of contents 

 

1. Key Insights

2. Executive Summary

3. Brain Cancer Market Overview at a Glance

4. Disease Background and Overview: Brain Cancer

5. Recognized Establishments

6. Treatment

7. National Comprehensive Cancer Network (NCCN) Guidelines for Central Nervous System Cancers (2020)

8. Neurological and vascular complications of primary and secondary brain tumors: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up (2020)

9. NICE Guidelines: Brain tumors (primary) and brain metastases in adults (2018)

10. Treatment Algorithm

11. Epidemiology and Patient Population

12. Country-wise Epidemiology of Brain Tumors

12.1. United States

12.2. EU5 Countries

12.3. Germany

12.4. France

12.5. Italy

12.6. Spain

12.7. United Kingdom

12.8. Japan

13. Unmet Needs

14. Marketed Drugs

14.1. Avastin: Genentech

14.2. Temodar/Temodal: Merck

15. Emerging Drugs

15.1. Key Competitors

15.2. Eflornithine + Lomustine: Orbus Therapeutics

15.3. Ofranergene obadenovec (VB-111): VBL Therapeutics

15.4. Trans Sodium Crocetinate: Diffusion Pharmaceuticals

15.5. Regorafenib: Bayer

15.6. Durvalumab (MEDI4736): MedImmune

15.7. Tasadenoturev (DNX-2401): DNAtrix

15.8. ONC201: Oncoceutics

15.9. Selinexor (KPT-330): Karyopharm Therapeutics

15.10. VBI-1901: VBI Vaccines

15.10.3. Safety and Efficacy

15.11. Paxalisib (GDC-0084): Kazia Therapeutics

15.12. AV-GBM-1: Aivita Biomedical

15.13. MDNA55: Medicenna Therapeutics

15.14. VAL-083 (Dianhydrogalactitol): Kintara Therapeutics

15.15. Pomalidomide: Bristol-Myers Squibb

15.16. LP561A1 (2-OHOA): Laminar Pharmaceuticals

15.17. ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics

15.18. Ad-RTS-hIL-12 + Veledimex: Ziopharm

15.19. Everolimus (RAD001): Novartis

15.20. INO-5401+ INO-9012+ Cemiplimab (REGN2810): Inovio Pharmaceuticals

16. Market Access and Reimbursement

17. Brain Cancer: Seven Major Market Analysis

18. 7MM Market Outlook

19. Case Reports

20. Market Drivers

21. Market Barriers

22. SWOT Analysis

23. KOL Reviews

24. Appendix

25. DelveInsight Capabilities

 

Request sample pages for more information on Brain Cancer Market Report

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/ghaziabadonline/gandhinagarnews.org/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share